Dynavax Reports Second Quarter 2014 Financial Results and Safety and Pharmacodynamic Results for Asthma and Lupus Drug

Dynavax Reports Second Quarter 2014 Financial Results and Safety and  Pharmacodynamic Results for Asthma and Lupus Drug Candidates  BERKELEY, CA -- (Marketwired) -- 08/07/14 --  Dynavax Technologies Corporation (NASDAQ: DVAX) today reported financial results for the second quarter ended June 30, 2014 and pharmacodynamic and safety results from clinical studies of its asthma drug candidate partnered with AstraZeneca and its systemic lupus erythematosus (SLE) drug candidate partnered with GlaxoSmithKline.  Second quarter 2014 financial results  Dynavax had $154.3 million in cash, cash equivalents and marketable securities as of June 30, 2014. Total operating expenses for the quarter ended June 30, 2014 of $27.9 million increased by $10.4 million compared to the quarter ended March 31, 2014 as a result of the initiation of HBV-23 and significant subject enrollment in this pivotal phase 3 trial during the quarter.   "We are very pleased with our progress on HBV-23," said Eddie Gray, Chief Executive Officer of Dynavax. "HEPLISAV-B will, if approved, provide patients a valuable alternative to currently available vaccines, and we are committed to bringing this important product to the market. In parallel, we are developing our pipeline to take full advantage of our platform and expertise in TLR immune modulation."   In April 2014, Dynavax initiated HBV-23, a large safety and immunogenicity study of its investigational adult hepatitis B vaccine. The study was designed to provide a sufficiently-sized safety database for the U.S. Food and Drug Administration to complete its review of the HEPLISAV-B Biologics License Application. It is being conducted at 40 sites in the U.S. and will include approximately 8,250 subjects. Dynavax expects that all HBV-23 study subjects will be enrolled by the end of 2014 and all follow-up visits will be completed by the fourth quarter of 2015.  Safety and pharmacodynamic results for asthma and SLE drug candidates  In a Phase 1 study, 4 weekly doses of a TLR9 agonist, AZD1419, or placebo were delivered by inhalation to 45 healthy volunteers. Ascending doses up to 15.4 mg/week for 4 weeks were well tolerated and no serious adverse events were observed in treated subjects. Secondary endpoints assessing pharmacodynamics were met, with dose-dependent induction of interferon-regulated genes in sputum and blood cells. Based on these results, Dynavax and its collaboration partner, AstraZeneca, are evaluating protocols for a clinical trial in patients with asthma.   In a Phase 1b/2a study, the safety and pharmacodynamics of a bifunctional TLR7 and TLR9 inhibitor, DV1179, were assessed in 52 SLE patients screened for elevated expression of interferon-regulated genes. DV1179 did not meet the primary or secondary pharmacodynamic endpoints related to reduction in interferon alpha-regulated genes. Doses up to 60 mg/week for 8 weeks were well tolerated. The most common adverse events were injection site reactions. GlaxoSmithKline will review the data package and determine whether to exercise its option to license DV1179.  About Dynavax  Dynavax, a clinical-stage biopharmaceutical company, discovers and develops novel vaccines and therapeutics in the areas of infectious and inflammatory diseases and oncology. Dynavax's lead product candidate is HEPLISAV-B, a Phase 3 investigational adult hepatitis B vaccine. For more information visit www.dynavax.com.  Forward-Looking Statements  This press release contains "forward-looking" statements, including expectations for the conduct, timing and sufficiency of an additional clinical trial for HEPLISAV-B and plans to continue clinical development of AZD1419. Actual results may differ materially from those set forth in this press release due to the risks and uncertainties inherent in our business, including whether successful clinical and regulatory development and review and approval of HEPLISAV-B and our process for its manufacture can occur without significant delay or additional studies; whether our studies and manufacturing efforts are sufficient to support registration for commercialization of HEPLISAV-B in either or both of the US and Europe; the timing for and costs of achieving the size of the safety database; the results of clinical trials and the impact of those results on the initiation and completion of subsequent trials and issues arising in the regulatory process, including whether a US or European licensure application will be approved; our ability to obtain additional financing to support the development and commercialization of HEPLISAV-B and our other operations; possible claims against us, including enjoining sales of HEPLISAV-B, based on the patent rights of others; and other risks detailed in the "Risk Factors" section of our current periodic reports with the SEC. We undertake no obligation to revise or update information herein to reflect events or circumstances in the future, even if new information becomes available. Information on Dynavax's website at www.dynavax.com is not incorporated by reference in our current periodic reports with the SEC.                                                                                                                                                                                      DYNAVAX TECHNOLOGIES CORPORATION                                          CONSOLIDATED STATEMENTS OF OPERATIONS                                       (In thousands, except per share amounts)                                                   (Unaudited)                                                                                                                                                    Three Months Ended   Six Months Ended                                             June 30,            June 30,                                            ------------------  ------------------                                         2014      2013      2014      2013                                         --------  --------  --------  --------  Revenues:                                                                      Collaboration revenue              $  2,031  $  1,356  $  4,404  $  2,239    Grant revenue                         1,007     1,395     2,132     2,155    Service and license revenue              10       641        10     1,083                                       --------  --------  --------  --------  Total revenues                          3,048     3,392     6,546     5,477                                                                               Operating expenses:                                                            Research and development             23,639    12,805    36,870    26,969    General and administrative            4,085     7,636     8,242    16,436    Unoccupied facility expense             178         -       255         -                                       --------  --------  --------  --------  Total operating expenses               27,902    20,441    45,367    43,405                                       --------  --------  --------  --------                                                                               Loss from operations                  (24,854)  (17,049)  (38,821)  (37,928)                                                                              Interest income                            55        54       120       126  Interest expense                            -       (27)        -       (59) Other income (expense)                     22      (142)       84      (128)                                      --------  --------  --------  --------                                                                               Net loss                             $(24,777) $(17,164) $(38,617) $(37,989)                                      ========  ========  ========  ========                                                                               Basic and diluted net loss per share $  (0.09) $  (0.09) $  (0.15) $  (0.21)                                      ========  ========  ========  ========                                                                               Shares used to compute basic and                                              diluted net loss per share           262,861   182,913   262,863   182,934                                       ========  ========  ========  ========                                                                                                                                                                                                                                                                                                                                            DYNAVAX TECHNOLOGIES CORPORATION                                                SELECTED BALANCE SHEET DATA                                                        (In thousands)                                                                 (Unaudited)                                                                                                                                                                  June 30,    December 31,                                                       2014          2013                                                      ------------- ------------- Assets                                                                         Cash, cash equivalents and marketable                                         securities                                    $     154,313 $     189,376   Property and equipment, net                            8,789         8,706   Goodwill                                               2,557         2,579   Other assets                                           7,806         3,961                                                  ------------- ------------- Total assets                                     $     173,465 $     204,622                                                  ============= =============                                                                              Liabilities and stockholders'equity                                            Deferred revenues                              $       8,294 $       7,298   Other liabilities                                     14,501        11,030                                                  ------------- -------------   Total liabilities                                     22,795        18,328   Stockholders' equity                                 150,670       186,294                                                  ------------- ------------- Total liabilities and stockholders' equity       $     173,465 $     204,622                                                  ============= =============     Contact: Michael Ostrach Chief Business and Principal Financial Officer 510-665-7257 mostrach@dynavax.com     
Press spacebar to pause and continue. Press esc to stop.